ENDRA Life Sciences Regains Nasdaq Compliance, Advances Innovative Solutions for Liver Health

ENDRA Life Sciences Advances Compliance and Focuses on Innovative Health Solutions

ENDRA Life Sciences Inc., headquartered in Ann Arbor, Michigan, announces a significant operational milestone by regaining compliance with the Nasdaq Stock Market's minimum bid price requirement, as confirmed on November 21, 2024. This achievement, under Nasdaq Listing Rule 5550(a)(2), allows the company to redirect its efforts toward enhancing its innovative business strategies, as highlighted by acting CEO Alex Tokman during an August conference call. ENDRA is widely recognized for its revolutionary Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which enables the assessment of tissue fat content and real-time monitoring of tissue ablation in minimally invasive medical procedures.

The primary application of ENDRA’s TAEUS® technology centers around measuring liver fat, a critical factor in evaluating and monitoring steatotic liver disease (SLD) and metabolic dysfunction-associated steatohepatitis (MASH). These conditions are of growing concern, affecting over two billion individuals globally and currently lacking effective diagnostic tools. By providing a non-invasive method to assess liver fat, ENDRA aims to fill a significant healthcare gap, potentially transforming the approach to diagnosing and managing liver-related disorders. The company is poised for growth as it seeks to implement its technology in clinical settings and address the pressing health challenges posed by these diseases.

As ENDRA looks to the future, it expresses optimism regarding potential FDA requirements for clinical trials and anticipates a timeline for regulatory approvals and product launches. However, the company also recognizes the inherent risks and uncertainties associated with its forward-looking statements regarding business strategies and financial projections. This cautious optimism reflects ENDRA’s understanding of the complexities involved in bringing innovative medical technologies to market. For more information on ENDRA Life Sciences and its pioneering TAEUS® technology, interested parties are encouraged to visit their official website at www.endrainc.com.

In conclusion, ENDRA Life Sciences’ recent compliance with Nasdaq strengthens its position in the industry as it focuses on addressing critical health issues associated with liver conditions. The company’s commitment to innovation and adherence to regulatory standards sets the stage for significant developments in the field of medical diagnostics. Through its advanced TAEUS® technology, ENDRA is well-positioned to make a meaningful impact on the healthcare landscape, providing solutions that could improve the lives of millions affected by liver diseases.